/
Biological products, (no diagnostic substances) company · DE · FY ends Dec · Revenue $11M · -2776.87% margin · -$213M FCF
The business is unprofitable at the operating level (-1971.59% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 53.4% YoY with margins expanding 1750.5pp.
Negative free cash flow of -$236M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$11M
▲ +53.4% YoY
Net Income (TTM)
-$273M
▲ +18.1% YoY
Op. Margin
-2776.87%
▲ +1750.5pp YoY
ROIC
-35.84%
▲ +2.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$213M
▲ +6.1% YoY
Op. Cash Flow (TTM)
-$213M
▲ +5.5% YoY
Net Debt
-$173M
Net Cash Position
Cash & Equiv.
$205M
5Y CAGR: -28.6%
Continue Research